alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Q2223K'],"[{'ncitCode': 'C48387', 'drugName': 'Everolimus'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 875, 'code': '', 'color': 'Orange', 'name': '', 'mainType': {'id': None, 'name': 'Renal Cell Carcinoma', 'tumorForm': 'SOLID'}, 'tissue': 'Kidney', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['24622468'],[],"Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) that is NCCN-listed and FDA-approved for patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. In a study of five patients with RCC who previously responded to rapalogs (median duration 28 months), 11/14 specimens had genomic alterations in TSC1 and MTOR (Q2223K, n = 1) that had activating effects on mTOR signaling (PMID: 24622468)."
['Oncogenic Mutations'],"[{'ncitCode': 'C48387', 'drugName': 'Everolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
['Oncogenic Mutations'],"[{'ncitCode': 'C1844', 'drugName': 'Temsirolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
